Immune Stress-induced Tumor Mutation Burden and Neoantigen Expression in 4T1 Mammary Cancer Cells: A Potential Mechanism for Long-term Survival in Patients Treated With Immune Checkpoint Inhibitors.

Saved in:
Bibliographic Details
Title: Immune Stress-induced Tumor Mutation Burden and Neoantigen Expression in 4T1 Mammary Cancer Cells: A Potential Mechanism for Long-term Survival in Patients Treated With Immune Checkpoint Inhibitors.
Authors: Ishiguro T; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan., Takeda K; Laboratory of Cell Biology, Biomedical Research Core Facilities, Graduate School of Medicine, Juntendo University, Tokyo, Japan., Takayanagi D; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan., Mura E; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan., Suzuki R; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan., Tsurui T; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan., Iriguchi N; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan., Hirasawa Y; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan., Ohkuma R; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan., Shimokawa M; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan., Ariizumi H; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan., Kubota Y; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan., Horiike A; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan., Izumizaki M; Department of Physiology, School of Medicine, Showa University, Tokyo, Japan., Wada S; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology & Therapeutics, Showa University, Tokyo, Japan., Yoshimura K; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.; Department of Clinical Immuno-Oncology, Clinical Research Institute of Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan., Hoffman RM; AntiCancer Inc., San Diego, CA, U.S.A.; Department of Surgery, University of California, San Diego, CA, U.S.A., Tsunoda T; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan; ttsunoda@med.showa-u.ac.jp.
Source: Cancer genomics & proteomics [Cancer Genomics Proteomics] 2025 Jan-Feb; Vol. 22 (1), pp. 1-12.
Publication Type: Journal Article
Journal Info: Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 101188791 Publication Model: Print Cited Medium: Internet ISSN: 1790-6245 (Electronic) Linking ISSN: 11096535 NLM ISO Abbreviation: Cancer Genomics Proteomics Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1790-6245
DOI:10.21873/cgp.20481